🇺🇸 FDA
Patent

US 11096910

Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease

granted A61KA61K31/17A61K31/18

Quick answer

US patent 11096910 (Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease) held by The Board of Regents of the University of Texas System expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/17, A61K31/18, A61K31/202, A61K31/4196